If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Research Agreement with Arysta LifeScience

27 Apr 2012 11:49

RNS Number : 2414C
Plant Health Care PLC
27 April 2012
 

27 April 2012

 

Plant Health Care plc

 

PLANT HEALTH CARE TO CONDUCT RESEARCH ON

HARPIN PROTEIN WITH ARYSTA LIFESCIENCE

 

 

Plant Health Care, a leading provider of naturally-derived products to the global agriculture markets, announces that it has signed a research agreement with Arysta LifeScience to evaluate Harpin commercially as a foliar spray in combination with a number of Arysta LifeScience's products.

 

 

Harpin is a leading PHC product and has been shown to increase yields significantly on a variety of crops when applied alone or in combination with other active ingredients. Arysta LifeScience will test Harpin formulations in combination with a number of its actives. Harpin technology offers yield improvement as a result of suppression of pests, such as nematodes, and defense against damaging diseases, as well as additive plant health benefits. Under this agreement, improvements in yield, plant health and product efficacy will be evaluated in a range of crops and environmental situations.

 

 

John Brady, CEO of Plant Health Care, commented: "We are excited to establish a testing programme with Arysta LifeScience, an innovative global player in the crop protection industry with annual sales of $1.6 billion. Arysta LifeScience has been highly successful in incorporating new technologies into its extensive product portfolio and, with its global reach, a successful outcome will be a major benefit to PHC. We are optimistic that Arysta LifeScience's testing efforts will lead to eventual commercial development of an innovative high return product for growers worldwide."

 

 

Bill Lewis, head of global business initiatives, Arysta LifeScience, said: "Harpin technology has the potential to bring additional value to Arysta LifeScience's existing line of products and we are excited about the opportunity to evaluate the Harpin technology."

 

 

- ENDS -

 

 

About Plant Health Care plc: Plant Health Care plc ("PHC") is a leading provider of naturally-derived products for plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United States, PHC currently has approximately 40 employees and has operations in the United States, Mexico, the United Kingdom, Spain and the Netherlands. The Company's ordinary shares have been quoted on the Alternative Investment Market ("AIM") of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") since February 2010 (ticker symbol/ mnemonic: PHC).

 

PHC's products are aimed at agriculture industries and are environmentally beneficial. Through the commercialisation of these products, PHC is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management. Further information is available at: www.planthealthcare.com.

 

 

 

For further information, please contact:

 

 

 

Plant Health Care plc

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

Stephen Weaver, Finance Director

Tel: +1-412-826-5488 x151

sweaver@planthealthcare.com

Nomura Code Securities

Tel: +44 (0) 20 7776 1200

Claire Terlouw / Chris Golden

www.nomuracode.com

Powerscourt

Tel: +44 (0) 20 7250 1446

Paul Durman / Nick Dibden

paul.durman@powerscourt-group.com

nick.dibden@powerscourt-group.com

 

 

 

 

 

About Arysta LifeScience Corporation

Headquartered in Tokyo, Japan, Arysta LifeScience is the world's largest privately held crop protection and life science company with 2011 revenues of JPY125.8 billion (US$1.6 billion). An entrepreneurial provider of crop protection and life science products in more than 125 countries worldwide, Arysta LifeScience specialises in marketing and distribution of respected crop protection brands and life science products in harmony with the needs of global partners. More information on the company is available at: www.arystalifescience.com.

 

Contact:

Linda Frerichs Global Communications Manager

Arysta LifeScience Corporation

919-678-4948

linda.frerichs@arystalifescience.com

 

Tara Hart Public Relations Manager

Woodruff Sweitzer

816-255-1960

thart@woodruffsweitzer.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAELXAFPAEFF
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.